Table 1.
Summary of available definitions and timing of ICI resumption.
| Study | Resumption Definition | Median Time before Resumption |
|---|---|---|
| Abou Alaiwi et al. [31] | Dose interruption for at least 1 week due to irAEs | 0.9 (range: 0.2–31.6) months |
| Abu Sbeih et al. [32] | ICI resumption after suspension because of IMDC onset | 49 (IQR: 23–136) days |
| Allouchery et al. [33] | Discontinued ICI before rechallenge for a period at least equal to twice the duration of a cycle | 56 (IQR: 42–84) days |
| Bhatlapenumarthi et al. [30] | Rechallenge after irAE with the same drug and dose | 2–30 weeks depending on irAE type and severity |
| Brunot et al. [34] | Washout between ipilimumab and first dose of anti-PD-1 | 25 weeks (range: 2–194) |
| Cortazar et al. [35] | Readministration of the same or different ICI | 1.8 months (IQR: 1.2–11.0) after diagnosis of AKI- irAE |
| de Malet et al. [36] | Second-irAE treatment with ICIs after GI-irAE | 1.1 months (range: 0.1–32.6) after the end of GI irAE |
| Gobbini et al. [37] | At least 12 weeks after discontinuation because of toxicity, disease progression or clinical decision | NR |
| Gupta et al. [38] | Discontinuation then reinitiation with same, different class or ICI combination | 1.9 months (IQR: 1.1–4.0) after initial irAE |
| Li et al. [39] | ICI resumption after high-grade ICI hepatitis resolution | 51 days (IQR: 15–77) |
| Mouri et al. [40] | Treatment delay of longer than 4 weeks due to an irAE | NR |
| Patrinely et al. [29] | Initiation of ICI after hepatitis resolution | 14 days (median days) |
| Pollack et al. [41] | Anti-PD-1 resumption after combined anti-CTLA-4 and anti-PD-1 | 58 days (range: 14–395) |
| Santini et al. [42] | Treatment delay longer than one week between planned doses of ICI | 32 days (range: 7–177) |
| Simonaggio et al. [43] | Readministration of the same drug class in the same patient | NR |
| Ravi et al. [44] | At least 2 separate lines of ICI (alone or in combination with other therapies). | NR |
AKI: Acute kidney injury; GI: gastro-intestinal; ICI: immunological checkpoint inhibitor(s); IQR (interquartile range); irAE: immune-related adverse event; IMDC: immune-mediated diarrhea and colitis; NR: not reported.